TNFRSF17 and Miyoshi myopathy: The first and thus far only ADC approved for MM is belantamab mafodotin (Blenrep® by GSK, Brentford, UK), an afucosylated humanized BCMA-targeted antibody that is coupled to the tubular polymerization blocker monomethyl auristatin F (MMAF, mafodotin) by a noncleavable maleimidocaproyl linker.